Postoperative Analgesia With Ketorolac Is Associated With Decreased Mortality After Isolated Coronary Artery Bypass Graft Surgery in Patients Already Receiving Aspirin: A Propensity-Matched Study

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 21, Issue 6, 2007, Pages 820-826

  Engoren, Milo C ^a,b   Habib, Robert H ^a,b   Zacharias, Anoar ^a,b   Dooner, John ^b   Schwann, Thomas A ^a,b   Riordan, Christopher J ^a,b   Durham, Samuel J ^a,b   Shah, Aamir ^a,b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b ST VINCENT MERCY MEDICAL CENTER   (United States)

Author keywords

coronary artery bypass graft surgery; ketorolac; propensity matching; statistics; survival analysis

Indexed keywords

ACETYLSALICYLIC ACID; DIAZEPAM; FENTANYL; ISOFLURANE; KETOROLAC; MORPHINE; OXYCODONE; PANCURONIUM; PARACETAMOL; ROCURONIUM; THIOPENTAL; VECURONIUM; WARFARIN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; EXTUBATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PAIN; POSTOPERATIVE ANALGESIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KETOROLAC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN, POSTOPERATIVE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 36549081331     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2007.01.024     Document Type: Article

References (37)

1. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
2. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus nonselective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 363 (2004) 1751-1756
3. Garcia Rodriguez L.A., Varas-Lorenzo C., Maguire A., et al. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109 (2004) 3000-3006
4. Ray W.A., Stein C.M., Hall K., et al. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 359 (2002) 118-123
5. Patel T.N., and Goldberg K.C. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 164 (2004) 852-856
6. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
7. Ranucci M., Cazzaniga A., Soro G., et al. Postoperative analgesia for early extubation after cardiac surgery. A prospective, randomized trial. Minerva Anestesiol 65 (1999) 859-865
8. Engoren M., Luther G., and Fenn-Buderer N. A Comparison of fentanyl, sufentanil, and remifentanil for "fast-track" cardiac anesthesia. Anesth Analg 93 (2001) 859-864
9. Niemi T.T., Backman J.T., Syrjala M.T., et al. Platelet dysfunction after intravenous ketorolac or propacetamol. Acta Anaesthesiol Scand 44 (2000) 69-74
10. Bozzo J., Escolar G., Hernandez M.R., et al. Prohemorrhagic potential of dipyrone, ibuprofen, ketorolac, and aspirin: Mechanisms associated with blood flow and erythrocyte deformability. J Cardiovasc Pharmacol 38 (2001) 183-190
11. Gavaghan T.P., Gebski V., and Baron D.W. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 83 (1991) 1526-1533
12. Rosenbaum P.R., and Rubin D.B. The bias due to incomplete matching. Biometrics 41 (1985) 103-116
13. Schoenfeld D.A. Sample-size formula for the proportional-hazards regression model. Biometrics 39 (1983) 499-503
14. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
15. Ott E., Nussmeier N.A., Duke P.C., et al. Multicenter Study of Perioperative Ischemia (McSPI) Research Group; Ischemia Research and Education Foundation (IREF) Investigators. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125 (2003) 1481-1492
16. Davies G.C., Sobel M., and Salzman E.W. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Circulation 61 (1980) 808-814
17. Yilmaz M.B., Balbay Y., Caldir V., et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 115 (2005) 25-29
18. Mangano D.T. Multicenter study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 347 (2002) 1309-1317
19. Poston R.S., Gu J., Brown J.M., et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 131 (2006) 122-130
20. Rajah S.M., Nair U., Rees M., et al. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 107 (1994) 1146-1153
21. Shufflebarger J.V., Doyle J., Roth T., et al. The effect of ketorolac on microvascular thrombosis in an experimental rabbit model. Plast Reconstr Surg 98 (1996) 140-145
22. Zhang Z.H., Wei S.G., Francis J., et al. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: The role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 284 (2003) R916-R927
23. Granados-Soto V., Flores-Murrieta F.J., Castaneda-Hernandez G., et al. Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac. Eur J Pharmacol 277 (1995) 281-284
24. Capone M.L., Sciulli M.G., Tacconelli S., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45 (2005) 1295-1301
25. Warner T.D., Giuliano F., Vojnovic I., et al. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci U S A 93 (1999) 7563-7568
26. Fiorucci S., Distrutti E., de Lima O.M., et al. Relative contribution of acetylated cyclooxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 17 (2003) 1171-1173
27. Chiang N., Arita M., and Serhan C.N. Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 163-177
28. Filep J.G., Khreiss T., and Jozsef L. Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal transduction. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 257-262
29. Baker C.S.R., Hall R.J.C., Evans T.J., et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19 (1999) 646-655
30. Beattie W.S., Warriner C.B., Etches R., et al. The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgesic morphine regimen reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty. Anesth Analg 84 (1997) 715-722
31. Kimmel S.E., Berlin J.A., Kinman J.L., et al. Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiol Drug Saf 11 (2002) 113-119
32. Glassman S.D., Rose S.M., Dimar J.R., et al. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 23 (1998) 834-838
33. Park S.-Y., Moon S.-H., Park M.-S., et al. The effects of ketorolac injected via patient-controlled analgesia postoperatively on spinal fusion. Yonsei Med J 46 (2005) 245-251
34. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Int Med 127 (1997) 757-763
35. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase-2 selective and nonselective nonsteroidal anti-inflammatory drugs: Nested case-control study. Lancet 365 (2005) 475-481
36. Kimmel S.E., Berlin J.A., Reilly M., et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142 (2005) 157-164
37. Solomon D.H., Schneeweiss S., Glynn R.J., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 (2004) 2068-2073